[go: up one dir, main page]

RU2018103873A3 - - Google Patents

Download PDF

Info

Publication number
RU2018103873A3
RU2018103873A3 RU2018103873A RU2018103873A RU2018103873A3 RU 2018103873 A3 RU2018103873 A3 RU 2018103873A3 RU 2018103873 A RU2018103873 A RU 2018103873A RU 2018103873 A RU2018103873 A RU 2018103873A RU 2018103873 A3 RU2018103873 A3 RU 2018103873A3
Authority
RU
Russia
Application number
RU2018103873A
Other languages
Russian (ru)
Other versions
RU2715384C2 (en
RU2018103873A (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015902659A external-priority patent/AU2015902659A0/en
Application filed filed Critical
Publication of RU2018103873A publication Critical patent/RU2018103873A/en
Publication of RU2018103873A3 publication Critical patent/RU2018103873A3/ru
Application granted granted Critical
Publication of RU2715384C2 publication Critical patent/RU2715384C2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
RU2018103873A 2015-07-06 2016-07-06 Therapeutic compounds and compositions for treating social and psychoactive substance-related disorders RU2715384C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015902659A AU2015902659A0 (en) 2015-07-06 Therapeutic compounds and compositions for treating social disorders and substance use disorders
AU2015902659 2015-07-06
PCT/AU2016/050588 WO2017004674A1 (en) 2015-07-06 2016-07-06 Therapeutic compounds and compositions for treating social disorders and substance use disorders

Publications (3)

Publication Number Publication Date
RU2018103873A RU2018103873A (en) 2019-08-06
RU2018103873A3 true RU2018103873A3 (en) 2019-09-04
RU2715384C2 RU2715384C2 (en) 2020-02-27

Family

ID=57684596

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018103873A RU2715384C2 (en) 2015-07-06 2016-07-06 Therapeutic compounds and compositions for treating social and psychoactive substance-related disorders

Country Status (18)

Country Link
US (3) US11033555B2 (en)
EP (1) EP3328864B1 (en)
JP (2) JP7089825B2 (en)
KR (1) KR102686349B1 (en)
CN (1) CN107922420B (en)
AU (1) AU2016289271B2 (en)
CA (1) CA2991236A1 (en)
DK (1) DK3328864T3 (en)
ES (1) ES2932194T3 (en)
HU (1) HUE060496T2 (en)
IL (1) IL256684B (en)
MX (1) MX389545B (en)
NZ (1) NZ738672A (en)
PL (1) PL3328864T3 (en)
PT (1) PT3328864T (en)
RU (1) RU2715384C2 (en)
SI (1) SI3328864T1 (en)
WO (1) WO2017004674A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE060496T2 (en) 2015-07-06 2023-03-28 Kinoxis Therapeutics Pty Ltd Therapeutic compounds and preparations for the treatment of social disorders and substance use disorders
RU2019120162A (en) * 2016-12-12 2021-01-12 Де Юниверсити Оф Сидней Non-peptide oxytocin receptor agonists
AU2019383052A1 (en) * 2018-11-23 2021-06-10 Macquarie University Methods for management of weight
JP7633236B2 (en) * 2019-09-06 2025-02-19 キノシス・セラピューティクス・ピーティーワイ・リミテッド Treating Opioid Withdrawal
CA3191811A1 (en) * 2020-09-07 2022-03-10 Hugh ALSOP Salts and crystals
AU2021401996A1 (en) * 2020-12-14 2023-07-13 Kinoxis Therapeutics Pty Ltd Oxytocin receptor modulators
EP4308127A4 (en) * 2021-03-18 2025-01-01 Kinoxis Therapeutics Pty Ltd TREATMENT METHODS
CN115677585B (en) * 2022-10-31 2024-03-19 上海群力化工有限公司 Synthesis process of formaldehyde pyrazole derivative
CN120282952A (en) 2022-11-09 2025-07-08 三菱瓦斯化学尼克斯株式会社 Process for producing 1-alkyl-5-hydroxypyrazole
WO2025172368A1 (en) 2024-02-13 2025-08-21 Syngenta Crop Protection Ag (5-isoxazol-3-yl)-[4-(pyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone derivatives for use as fungicides
WO2025191053A1 (en) 2024-03-14 2025-09-18 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2025210095A1 (en) 2024-04-03 2025-10-09 Syngenta Crop Protection Ag Microbiocidal tetrahydroisoquinoline compounds
CN119386023A (en) * 2024-10-25 2025-02-07 南方医科大学南方医院 Application of diltiazem in preparing medicine for treating autism

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115515D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Oxytocin agonisys
EP1512687A1 (en) * 2003-09-05 2005-03-09 Ferring B.V. Piperazines as oxytocin agonists
EP1632494A1 (en) * 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
KR20080063848A (en) 2005-10-24 2008-07-07 와이어쓰 Tricyclic Compounds Useful as Oxytocin Receptor Agonists
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
EP2571360A4 (en) 2010-05-19 2013-07-31 Univ North Carolina METHODS AND FORMULATIONS FOR THE TREATMENT BY OXYTOCINE OF DISORDERS RELATED TO THE USE OF TOXIC SUBSTANCES, PSYCHIATRIC DISORDERS AND OTHER DISORDERS
GB201015371D0 (en) 2010-09-14 2010-10-27 Optinose As Nasal delivery
KR20140124465A (en) 2013-04-17 2014-10-27 인제대학교 산학협력단 The Use of Oxytocin for Controlling Social Emotional-Related Behaviors
HUE060496T2 (en) 2015-07-06 2023-03-28 Kinoxis Therapeutics Pty Ltd Therapeutic compounds and preparations for the treatment of social disorders and substance use disorders
JP7633236B2 (en) 2019-09-06 2025-02-19 キノシス・セラピューティクス・ピーティーワイ・リミテッド Treating Opioid Withdrawal
EP4308127A4 (en) 2021-03-18 2025-01-01 Kinoxis Therapeutics Pty Ltd TREATMENT METHODS

Also Published As

Publication number Publication date
CA2991236A1 (en) 2017-01-12
IL256684B (en) 2022-06-01
EP3328864B1 (en) 2022-09-07
HK1252813A1 (en) 2019-06-06
CN107922420B (en) 2021-12-31
WO2017004674A1 (en) 2017-01-12
ES2932194T3 (en) 2023-01-16
MX389545B (en) 2025-03-20
CN107922420A (en) 2018-04-17
US20240245706A1 (en) 2024-07-25
IL256684A (en) 2018-03-29
MX2017017171A (en) 2018-04-30
RU2715384C2 (en) 2020-02-27
JP2022130418A (en) 2022-09-06
DK3328864T3 (en) 2022-12-05
EP3328864A4 (en) 2019-01-09
JP7490018B2 (en) 2024-05-24
NZ738672A (en) 2022-11-25
AU2016289271B2 (en) 2020-12-03
JP7089825B2 (en) 2022-06-23
US11890287B2 (en) 2024-02-06
JP2018525351A (en) 2018-09-06
BR112018000059A2 (en) 2018-09-04
US20190290658A1 (en) 2019-09-26
HUE060496T2 (en) 2023-03-28
US12458648B2 (en) 2025-11-04
KR20180023992A (en) 2018-03-07
US20220362261A1 (en) 2022-11-17
EP3328864A1 (en) 2018-06-06
AU2016289271A1 (en) 2018-01-25
KR102686349B1 (en) 2024-07-17
PL3328864T3 (en) 2023-02-27
PT3328864T (en) 2022-12-07
SI3328864T1 (en) 2023-02-28
US11033555B2 (en) 2021-06-15
RU2018103873A (en) 2019-08-06

Similar Documents

Publication Publication Date Title
BR112017027930A2 (en)
RU2018103873A3 (en)
BR112018004010A2 (en)
BR102016015254A8 (en)
BR112018004028A2 (en)
BR112018002924A2 (en)
BR112018004090A2 (en)
BR112016023275A2 (en)
BR0009942B1 (en)
BR0009373B1 (en)
CN303066491S (en)
CN303066388S (en)
CN303066273S (en)
CN303068863S (en)
CN303069842S (en)
CN303070754S (en)
CN303070874S (en)
CN303071274S (en)
CN303071882S (en)
CN303069548S (en)
BR0215724B1 (en)
BR0206998B1 (en)
BR0010974B1 (en)
BR0009994B1 (en)
CN303066742S (en)